Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non - acute kidney injury (AKI) diseases

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 4, 2011, Pages 272-282

  Giasson, Janice ^a   Li, Guo Hua ^b   Chen, Yu ^a  

^a Horizon Health Network   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Biomarker; Diagnosis; NGAL; Non AKI diseases

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ACUTE KIDNEY FAILURE; ALLERGY; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANCA ASSOCIATED VASCULITIS; ATHEROSCLEROSIS; BETA THALASSEMIA; BLOOD; BODY FLUID; BRAIN ISCHEMIA; BRAIN TUMOR; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CORONARY ARTERY DISEASE; CROHN DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LIVER METASTASIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEPHROTIC SYNDROME; NON ACUTE KIDNEY INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY CANCER; OVARY POLYCYSTIC DISEASE; PANCREATITIS; PATENT DUCTUS ARTERIOSUS; PREGNANCY DIABETES MELLITUS; PREMATURITY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY DISTRESS SYNDROME; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSITIONAL CELL CARCINOMA; TUBULAR DYSFUNCTION; ULCERATIVE COLITIS; URINE;

EID: 79959996149     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811796117753     Document Type: Review

References (77)

1. Flower, D.R. The lipocalin protein family: structure and function. Biochem, J., 1996, 318, 1-14.
2. Mishra, J.; Ma, Q.; Prada, A.; Mitsnefes, M.; Zahedi, K.; Yang, J.; Barasch, J.; Devarajan, P. Identification of neutrophil gelatinaseassociated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol., 2003, 14, 2534-2543.
3. Bolignano, D.; Della, Torre, A.; Lacquaniti, A.; Costantino, G.; Fries, W.; Buemi, M. Neutrophil gelatinase-associated lipocalin levels in patients with crohn's disease undergoing treatment with infliximab. J. Investig. Med., 2010, 58, 569-5671.
4. Malyszko, J.; Malyszko, J.S.; Bachorzewska-Gajewska, H.; Poniatowski, B.; Dobrzycki, S.; Mysliwiec, M. Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant. Proc., 2009, 41, 158-161.
5. Devarajan, P. NGAL in acute kidney injury: from serendipity to utility. Am. J. Kidney Dis., 2008, 52, 395-399.
6. Szewczyk, M.; Wielkoszyński, T.; Zakliczyński, M.; Zembala, M. Plasma neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine, and glomerular filtration rate in patients after heart and lung transplantation. Transplant Proc., 2009, 41(8), 3242-3243.
7. Xu, S.; Venge, P. Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta., 2000, 1482, 298-307.
8. Mishra, J.; Mori, K.; Ma, Q.; Kelly, C.; Yang, J.; Mitsnefes, M.; Barasch, J.; Devarajan, P. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol., 2004, 15, 3073-3082.
9. Mori, K.; Lee, H.T.; Rapoport, D.; Drexler, I.R.; Foster, K.; Yang, J.; Schmidt-Ott, K.M.; Chen, X.; Li, J.Y.; Weiss, S.; Mishra, J.; Cheema, F.H.; Markowitz, G.; Suganami, T.; Sawai, K.; Mukoyama, M.; Kunis, C.; D'Agati, V.; Devarajan, P.; Barasch, J. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest., 2005, 115, 610-621.
10. Devarajan, P. Review: Neutrophil gelatinase-associated lipocalin: A troponin-like biomarker for human acute kidney injury. Nephrology (Carlton). 2010, 15, 419-28.
11. Devarajan, P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand. J. Clin. Lab. Invest. (Suppl)., 2008, 241, 89-94
12. Haase, M.; Bellomo, R.; Devarajan, P.; Schlattmann, P.; Haase-Fielitz, A. NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and metaanalysis. Am. J. Kidney Dis., 2009, 54, 1012-1024.
13. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am. J. Kidney Dis., 2002, 39, S1-S266.
14. Nishida, M.; Kawakatsu, H.; Okumura, Y.; Hamaoka, K. Serum and urinary NGAL levels in children with chronic renal diseases. Pediatr. Int., 2010, 52, 563-568.
15. Mitsnefes, M.M.; Kathman, T.S.; Mishra, J.; Kartal, J.; Khoury, P.R.; Nickolas, T.L.; Barasch, J.; Devarajan, P. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr. Nephrol., 2007, 22, 101-108.
16. Bolignano, D.; Lacquaniti, A.; Coppolino, G.; Donato, V.; Campo, S.; Fazio, M.R.; Nicocia, G.; Buemi, M. Neutrophil gelatinaseassociated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2009, 4, 337-344.
17. Bolignano, D.; Lacquaniti, A.; Coppolino, G.; Campo, S.; Arena, A.; Buemi, M. Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press. Res., 2008, 31, 255-258.
18. Malyszko, J.; Bachorzewska-Gajewska, H.; Sitniewska, E.; Malyszko, J.S.; Poniatowski, B.; Dobrzycki, S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in nondiabetic patients with stage 2-4 chronic kidney disease. Ren. Fail., 2008, 30, 625-628.
19. Bolignano, D.; Coppolino, G.; Lacquaniti, A.; Nicocia, G.; Buemi, M. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press. Res,. 2008, 31, 274-279.
20. Malyszko, J.; Malyszko, J.S.; Mysliwiec, M. Serum neutrophil gelatinase-associated lipocalin correlates with kidney function in renal allograft recipients. Clin. Transplant,. 2009, 23, 681-686.
21. Bolignano, D.; Coppolino, G.; Campo, S.; Aloisi, C.; Nicocia, G.; Frisina, N.; Buemi, M. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am. J. Nephrol., 2007, 27, 373-378.
22. Malyszko, J.; Malyszko, J.S.; Kozminski, P.; Koc-Zorawska, E.; Mysliwiec, M.; Macdougall, I. Possible Relationship between Neutrophil Gelatinase-Associated Lipocalin, Hepcidin, and Inflammation in Haemodialysed Patients. Nephron. Clin Pract., 2010, 115, c268-c275.
23. Bolignano, D.; Coppolino, G.; Romeo, A.; Lacquaniti, A.; Buemi, M. Neutrophil gelatinase-associated lipocalin levels in chronic haemodialysis patients. Nephrology (Carlton)., 2010, 15, 23-26.
24. Paragas, N.; Nickolas, T.L.; Wyatt, C.; Forster, C.S.; Sise, M.; Morgello, S.; Jagla, B.; Buchen, C.; Stella, P.; Sanna-Cherchi, S.; Carnevali, M.L.; Mattei, S.; Bovino, A.; Argentiero, L.; Magnano, A.; Devarajan, P.; Schmidt-Ott, K.M.; Allegri, L.; Klotman, P.; D'Agati, V.; Gharavi, A.G.; Barasch, J. Urinary NGAL marks cystic disease in HIV-associated nephropathy. J. Am. Soc. Nephrol,. 2009, 20, 1687-1692
25. Soler-García, A.A.; Johnson, D.; Hathout, Y.; Ray, P.E. Ironrelated proteins: candidate urine biomarkers in childhood HIVassociated renal diseases. Clin. J. Am. Soc. Nephrol., 2009, 4, 763-771.
26. Ding, H.; He, Y.; Li, K.; Yang, J.; Li, X.; Lu, R.; Gao, W. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin. Immunol., 2007, 123, 227-234.
27. Ichino, M.; Kusaka, M.; Kuroyanagi, Y.; Mori, T.; Morooka, M.; Sasaki, H.; Shiroki, R.; Shishido, S.; Kurahashi, H.; Hoshinaga, K. Urinary neutrophil-gelatinase associated lipocalin is a potential noninvasive marker for renal scarring in patients with vesicoureteral reflux. J. Urol., 2010, 183, 2001-7.
28. Suzuki, M.; Wiers, K.M.; Klein-Gitelman, M.S.; Haines, K.A.; Olson, J.; Onel, K.B.; O'Neil, K.; Passo, M.H.; Singer, N.G.; Tucker, L.; Ying, J.; Devarajan, P.; Brunner, H.I. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr. Nephrol., 2008, 23, 403-412.
29. Brunner, H.I.; Mueller, M.; Rutherford, C.; Passo, M.H.; Witte, D.; Grom, A.; Mishra, J.; Devarajan, P. Urinary neutrophil gelatinaseassociated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum., 2006, 54, 2577-2584.
30. Hinze, C.H.; Suzuki, M.; Klein-Gitelman, M.; Passo, M.H.; Olson, J.; Singer, N.G.; Haines, K.A.; Onel, K.; O'Neil, K.; Silverman, E.D.; Tucker, L.; Ying, J.; Devarajan, P.; Brunner, H.I. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum., 2009, 60, 2772-2781.
31. Rubinstein, T.; Pitashny, M.; Levine, B.; Schwartz, N.; Schwartzman, J.; Weinstein, E.; Pego-Reigosa, J.M.; Lu, T.Y.; Isenberg, D.; Rahman, A.; Putterman, C. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford),. 2010, 49, 960-971.
32. Wasilewska, A.; Zoch-Zwierz, W.; Taranta-Janusz, K.; Michaluk-Skutnik, J. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr. Nephrol., 2010, 25, 889-897.
33. Moreno-Navarrete, J.M.; Manco, M.; Ibáñez, J.; García-Fuentes, E.; Ortega, F.; Gorostiaga, E.; Vendrell, J.; Izquierdo, M.; Martínez, C.; Nolfe, G.; Ricart, W.; Mingrone, G.; Tinahones, F.; Fernández-Real, J.M. Metabolic endotoxemia and saturated fat contribute to circulating NGAL concentrations in subjects with insulin resistance. Int. J. Obes. (Lond)., 2010, 34, 240-249.
34. Yang, Y.H.; He, X.J.; Chen, S.R.; Wang, L.; Li, E.M.; Xu, L.Y. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine, 2009, 36, 45-51.
35. Bolignano, D.; Lacquaniti, A.; Coppolino, G.; Donato, V.; Fazio, M.R.; Nicocia, G.; Buemi, M. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press. Res., 2009, 32, 91-98.
36. D'Anna, R.; Baviera, G.; Corrado, F.; Giordano, D.; Recupero, S.; Di Benedetto, A. First trimester serum neutrophil gelatinaseassociated lipocalin in gestational diabetes. Diabet. Med., 2009, 26, 1293-1295.
37. Forsblad, J.; Gottsäter, A.; Persson, K.; Jacobsson, L.; Lindgärde, F. Clinical manifestations of atherosclerosis in an elderly population are related to plasma neopterin, NGAL and endothelin-1, but not to Chlamydia pneumoniae serology. Int. Angiol., 2002, 21, 173-179.
38. Elneihoum, A.M.; Falke, P.; Hedblad, B.; Lindgärde, F.; Ohlsson, K. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis, 1997, 131, 79-84.
39. Anwaar, I.; Gottsäter, A.; Hedblad, B.; Palmqvist, B.; Mattiasson, I.; Lindgärde, F. Endothelial derived vasoactive factors and leukocyte derived inflammatory mediators in subjects with asymptomatic atherosclerosis. Angiology, 1998, 49, 957-966.
40. Malyszko, J.; Bachorzewska-Gajewska, H.; Malyszko, J.S.; Pawlak, K.; Dobrzyckik, S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology (Carlton),. 2008, 13, 153-156.
41. Zografos, T.; Haliassos, A.; Korovesis, S.; Giazitzoglou, E.; Voridis, E.; Katritsis, D. Association of neutrophil gelatinaseassociated lipocalin with the severity of coronary artery disease. Am. J. Cardiol., 2009, 104, 917-920.
42. Damman, K.; van Veldhuisen, D.J.; Navis, G.; Voors, A.A.; Hillege, H.L. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur. J. Heart Fail., 2008, 10, 997-1000.
43. Yndestad, A.; Landrø, L.; Ueland, T.; Dahl, C.P.; Flo, T.H.; Vinge, L.E.; Espevik, T.; Frøland, S.S.; Husberg, C.; Christensen, G.; Dickstein, K.; Kjekshus, J.; Øie, E.; Gullestad, L.; Aukrust, P. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur. Heart J., 2009, 30, 1229-36.
44. Poniatowski, B.; Malyszko, J.; Bachorzewska-Gajewska, H.; Malyszko, J.S.; Dobrzycki, S. Serum neutrophil gelatinaseassociated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. Kidney Blood Press. Res., 2009, 32, 77-80.
45. Bolignano, D., Basile, G., Parisi, P., Coppolino, G., Nicocia, G., Buemi, M. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res., 2009, 12, 7-14.
46. Biezeveld, M.H., van Mierlo, G., Lutter, R., Kuipers, I.M., Dekker, T., Hack, C.E., Newburger, J.W., Kuijpers, T.W. Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases. Clin. Exp. Immunol., 2005, 141, 183-188.
47. Ohlsson, S.; Wieslander, J.; Segelmark, M. Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission. Clin. Exp. Immunol., 2003, 131, 528-535.
48. Chen, M.; Wang, F.; Zhao, M.H. Circulating neutrophil gelatinaseassociated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis. Rheumatology (Oxford)., 2009, 48, 355-358.
49. Elneihoum, A.M.; Falke, P.; Axelsson, L.; Lundberg, E.; Lindgärde, F.; Ohlsson, K. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke, 1996, 27, 1734-1738.
50. Anwaar, I.; Gottsäter, A.; Ohlsson, K.; Mattiasson, I.; Lindgärde, F. Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. Cerebrovasc. Dis., 1998, 8, 310-7.
51. Falke, P.; Elneihoum, A.M.; Ohlsson, K. Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc. Dis., 2000, 10, 97-101.
52. Fernández, C.A.; Yan, L.; Louis, G.; Yang, J.; Kutok, J.L.; Moses, M.A. The matrix metalloproteinase-9/neutrophil gelatinaseassociated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res., 2005, 11, 5390-5395.
53. Provatopoulou, X.; Gounaris, A.; Kalogera, E.; Zagouri, F.; Flessas, I.; Goussetis, E.; Nonni, A.; Papassotiriou, I.; Zografos, G. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer, 2009, 9, 390.
54. Smith, E.R.; Zurakowski, D.; Saad, A.; Scott, R. M, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin. Cancer Res., 2008, 14, 2378-86.
55. Villalva, C.; Sorel, N.; Bonnet, M.L.; Guilhot, J.; Mayeur-Rousse, C.; Guilhot, F.; Chomel, J.C.; Turhan, A.G. Neutrophil gelatinaseassociated lipocalin expression in chronic myeloid leukemia. Leuk. Lymphoma., 2008, 49, 984-988.
56. Martí, J.; Fuster, J., Hotter, G., Solà, A.M., Deulofeu, R., Modolo, M.M., Loera, M.A., Ferrer, J., Fondevila, C., García-Valdecasas, J.C. Serum neutrophil gelatinase-associated lipocalin in patients with colorectal liver metastases: preliminary results of an exploratory prospective study. Int. J. Biol. Markers., 2010, 25, 21-26.
57. Moniaux, N., Chakraborty, S., Yalniz, M., Gonzalez, J., Shostrom, V.K., Standop, J., Lele, S.M., Ouellette, M., Pour, P.M., Sasson, A.R., Brand, R.E., Hollingsworth, M.A., Jain, M., Batra, S.K. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br. J. Cancer, 2008, 98, 1540-1547.
58. Lim, R.; Ahmed, N.; Borregaard, N.; Riley, C.; Wafai, R.; Thompson, E.W.; Quinn, M.A.; Rice, G.E. Neutrophil gelatinaseassociated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factorinduced epithelio-mesenchymal transition. Int. J. Cancer, 2007, 120, 2426-2434.
59. Monier, F.; Mollier, S.; Guillot. M.; Rambeaud, J.J.; Morel, F.; Zaoui, P. Urinary release of 72 and 92 kDa gelatinases, TIMPs, NGAL and conventional prognostic factors in urothelial carcinomas. Eur. Urol., 2002, 42, 356-363.
60. Möller, H.; Ohlsson, K.; Linder, C.; Björkner, B.; Bruze, M. Cytokines and acute phase reactants during flare-up of contact allergy to gold. Am. J. Contact Dermat., 1998, 9, 15-22.
61. Möller, H.; Ohlsson, K.; Linder, C.; Björkner, B.; Bruze, M. The flare-up reactions after systemic provocation in contact allergy to nickel and gold. Contact Dermatitis., 1999, 40, 200-204.
62. Nielsen, O.H.; Gionchetti, P.; Ainsworth, M.; Vainer, B.; Campieri, M.; Borregaard, N.; Kjeldsen, L. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am. J. Gastroenterol., 1999, 94, 2923-2928.
63. Yilmaz, A.; Sevketoglu, E.; Gedikbasi, A.; Karyagar, S.; Kiyak, A.; Mulazimoglu, M.; Aydogan, G.; Ozpacaci, T.; Hatipoglu, S. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatr. Nephrol., 2009, 24, 2387-2392.
64. Shapiro, N.I.; Trzeciak, S.; Hollander, J.E.; Birkhahn, R.; Otero, R.; Osborn, T.M.; Moretti, E.; Nguyen, H.B.; Gunnerson, K.J.; Milzman, D.; Gaieski, D.F.; Goyal, M.; Cairns, C.B.; Ngo, L.; Rivers, E.P. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit. Care Med., 2009, 37, 96-104.
65. Petersson, U.; Borgström, A.; Ohlsson, K.; Fork, F.T.; Toth, E. Enzyme leakage, trypsinogen activation, and inflammatory response in endoscopic retrograde cholangiopancreatographyinduced pancreatitis. Pancreas., 2002, 24, 321-328.
66. Sveger, T.; Ohlsson, K.; Mörse, H.; Polberger, S.; Laurin, S. Plasma neutrophil lipocalin, elastase-alpha1-antitrypsin complex and neutrophil protease 4 in preterm infants with respiratory distress syndrome. Scand. J. Clin. Lab. Invest., 2003, 63, 89-92.
67. Capoluongo, E.; Vento, G.; Lulli, P.; Di Stasio, E.; Porzio, S.; Vendettuoli, V.; Tana, M.; Tirone, C.; Romagnoli, C.; Zuppi, C.; Ameglio, F. Epithelial lining fluid neutrophil-gelatinase-associated lipocalin levels in premature newborns with bronchopulmonary dysplasia and patency of ductus arteriosus. Int. J. Immunopathol. Pharmacol., 2008, 21, 173-179.
68. Roudkenar, M.H.; Halabian, R.; Oodi, A.; Roushandeh, A.M.; Yaghmai, P.; Najar, M.R.; Amirizadeh, N.; Shokrgozar, M.A. Upregulation of neutrophil gelatinase-associated lipocalin, NGAL/Lcn2, in beta-thalassemia patients. Arch. Med. Res., 2008, 39, 402-407.
69. D'Anna, R.; Baviera, G.; Giordano, D.; Todarello, G.; Corrado, F.; Buemi, M. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet. Gynecol. Scand., 2008, 87, 1370-1373.
70. D'Anna, R.; Baviera, G.; Giordano, D.; Todarello, G.; Russo, S.; Recupero, S.; Bolignano, D.; Corrado, F. Neutrophil gelatinaseassociated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet. Gynecol. Scand., 2010, 89, 275-278.
71. Chen, Y. Novel angiogenic factors for predicting preeclampsia: sFlt-1, PlGF, and soluble Endoglin. Open Clin. Chem. J., 2009, 2, 1-6.
72. Sveger, T.; Ohlsson, K.; Piitulainen, E. Adolescents with alpha1-antitrypsin deficiency have high alpha2-macroglobulin and low neutrophil lipocalin and elastase levels in plasma. Pediatr. Res., 1998, 44, 939-941.
73. Diamanti-Kandarakis, E.; Livadas, S.; Kandarakis, S.A.; Margeli, A.; Papassotiriou, I. Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur. J. Endocrinol., 2008, 158, 525-531.
74. Bolignano, D.; Coppolino, G.; Romeo, A.; De Paola, L.; Buemi, A.; Lacquaniti, A.; Nicocia, G.; Lombardi, L.; Buemi, M. Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. Nephrol. Dial. Transplant., 2009, 24, 3398-3403.
75. Pedersen, K.R.; Ravn, H.B.; Hjortdal, V.E.; Nørregaard, R.; Povlsen, J.V. Neutrophil gelatinase-associated lipocalin (NGAL): validation of commercially available ELISA. Scand. J. Clin. Lab. Invest., 2010, 70, 374-382.
76. Grenier, F.C.; Ali, S.; Syed, H.; Workman, R.; Martens, F.; Liao, M.; Wang, Y.; Wong, P.Y. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability. Clin. Biochem., 2010, 43, 615-620.
77. Mishra, J.; Dent, C.; Tarabishi, R.; Mitsnefes, M.M.; Ma, Q.; Kelly, C.; Ruff, S.M.; Zahedi, K.; Shao, M.; Bean, J.; Mori, K.; Barasch, J.; Devarajan, P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet, 2005, 365, 1231-1238.